Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis.

ABSTRACT:

Objective

Acid blocker therapy (ABT) has become common in cystic fibrosis (CF), despite insufficient evidence for benefits and studies showing potentially negative effects. We examined associations between ABT usage and growth, gut microbiome (GM), and early-onset lung disease in young children with CF.

Methods

One hundred and forty-five infants with CF born during 2012-2017, diagnosed through newborn screening by age 3 months and followed to 36 months of age at six CF centers were evaluated. Longitudinal data on growth, pancreatic functional status, pulmonary symptoms, and acid blocker medications were prospectively collected. Early-onset lung disease severity was evaluated by a clinical scoring system. GM composition was assessed by 16S rRNA methodology.

Results

ABT

SUBMITTER: Liu C 

PROVIDER: S-EPMC11615133 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature